LY-503,430 (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "LY-503,430" in Serbian language version.

refsWebsite

Global rank Serbian rank

5nih.gov

4^th place

8^th place

5doi.org

2^nd place

4^th place

1archive.org

6^th place

5^th place

archive.org (Global: 6^th place; Serbian: 5^th place)

Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P; et al. (2003). „LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 306 (2): 752—62. PMID 12730350. doi:10.1124/jpet.103.049445.

doi.org (Global: 2^nd place; Serbian: 4^th place)

O'neill, MJ; Murray, TK; Clay, MP; Lindstrom, T; Yang, CR; Nisenbaum, ES (2005). „LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease”. CNS Drug Reviews. 11 (1): 77—96. PMID 15867954. doi:10.1111/j.1527-3458.2005.tb00037.x. |first2= захтева |last2= у Authors list (помоћ); |first3= захтева |last3= у Authors list (помоћ); |first4= захтева |last4= у Authors list (помоћ); |first5= захтева |last5= у Authors list (помоћ); |first6= захтева |last6= у Authors list (помоћ)
Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P; et al. (2003). „LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 306 (2): 752—62. PMID 12730350. doi:10.1124/jpet.103.049445.
Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). „Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors”. The Journal of Pharmacology and Experimental Therapeutics. 319 (1): 293—8. PMID 16803862. doi:10.1124/jpet.106.105734.
O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). „AMPA receptor potentiators for the treatment of CNS disorders”. Current drug targets. CNS and neurological disorders. 3 (3): 181—94. PMID 15180479. doi:10.2174/1568007043337508. |first2= захтева |last2= у Authors list (помоћ); |first3= захтева |last3= у Authors list (помоћ); |first4= захтева |last4= у Authors list (помоћ)
O'neill, MJ; Witkin, JM (2007). „AMPA receptor potentiators: application for depression and Parkinson's disease”. Current drug targets. 8 (5): 603—20. PMID 17504104. doi:10.2174/138945007780618517. |first2= захтева |last2= у Authors list (помоћ)

nih.gov (Global: 4^th place; Serbian: 8^th place)

ncbi.nlm.nih.gov

O'neill, MJ; Murray, TK; Clay, MP; Lindstrom, T; Yang, CR; Nisenbaum, ES (2005). „LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease”. CNS Drug Reviews. 11 (1): 77—96. PMID 15867954. doi:10.1111/j.1527-3458.2005.tb00037.x. |first2= захтева |last2= у Authors list (помоћ); |first3= захтева |last3= у Authors list (помоћ); |first4= захтева |last4= у Authors list (помоћ); |first5= захтева |last5= у Authors list (помоћ); |first6= захтева |last6= у Authors list (помоћ)
Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P; et al. (2003). „LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 306 (2): 752—62. PMID 12730350. doi:10.1124/jpet.103.049445.
Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). „Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors”. The Journal of Pharmacology and Experimental Therapeutics. 319 (1): 293—8. PMID 16803862. doi:10.1124/jpet.106.105734.
O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). „AMPA receptor potentiators for the treatment of CNS disorders”. Current drug targets. CNS and neurological disorders. 3 (3): 181—94. PMID 15180479. doi:10.2174/1568007043337508. |first2= захтева |last2= у Authors list (помоћ); |first3= захтева |last3= у Authors list (помоћ); |first4= захтева |last4= у Authors list (помоћ)
O'neill, MJ; Witkin, JM (2007). „AMPA receptor potentiators: application for depression and Parkinson's disease”. Current drug targets. 8 (5): 603—20. PMID 17504104. doi:10.2174/138945007780618517. |first2= захтева |last2= у Authors list (помоћ)

LY-503,430 (Serbian Wikipedia)

archive.org (Global: 6th place; Serbian: 5th place)

doi.org (Global: 2nd place; Serbian: 4th place)

nih.gov (Global: 4th place; Serbian: 8th place)

ncbi.nlm.nih.gov

archive.org (Global: 6^th place; Serbian: 5^th place)

doi.org (Global: 2^nd place; Serbian: 4^th place)

nih.gov (Global: 4^th place; Serbian: 8^th place)